본문 바로가기
KERD
논문KCI 등재

Familial Pancreatic Cancer and Surveillance of High-Risk Individuals

Hiroyuki Matsubayashi|Kyoichi Takaori|Chigusa Morizane|Yoshimi Kiyozumi
거트앤리버 소화기연관학회협의회|2019.09|Gut and Liver|제13권 제5호|pp. 498-505|DOI 10.5009/gnl18449

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

TreatmentSurveillanceGeneticHigh riskFamilial pancreatic cancer

초록

Family history of pancreatic cancer (PC) is a risk factor for PC development, and the risk level correlates with the number of affected families. A case of PC with ≥1 PC cases in the first-degree relative is broadly defined as familial pancreatic cancer (FPC) and accounts for 5% to 10% of total PC cases. FPC possesses several epidemiological, genetic and clinicopathological aspects that are distinct from those of conventional PCs. In Western countries, FPC registries have been established since the 1990s, and high-risk individuals are screened to detect early PCs. For the pharmacotherapy of FPC, especially in cases with germline pathogenic BRCA mutations, regimens using platinum and poly (ADP-ribose) polymerase inhibitor have recently been studied for their effectiveness. To date, the concept of FPC has prevailed in Western countries, and it has begun to infiltrate into Eastern countries. As the genetic background and environmental conditions vary in association with ethnicity and living area, we need to establish our own FPC registries and accumulate data in Asian countries.

Abstract

Family history of pancreatic cancer (PC) is a risk factor for PC development, and the risk level correlates with the number of affected families. A case of PC with ≥1 PC cases in the first-degree relative is broadly defined as familial pancreatic cancer (FPC) and accounts for 5% to 10% of total PC cases. FPC possesses several epidemiological, genetic and clinicopathological aspects that are distinct from those of conventional PCs. In Western countries, FPC registries have been established since the 1990s, and high-risk individuals are screened to detect early PCs. For the pharmacotherapy of FPC, especially in cases with germline pathogenic BRCA mutations, regimens using platinum and poly (ADP-ribose) polymerase inhibitor have recently been studied for their effectiveness. To date, the concept of FPC has prevailed in Western countries, and it has begun to infiltrate into Eastern countries. As the genetic background and environmental conditions vary in association with ethnicity and living area, we need to establish our own FPC registries and accumulate data in Asian countries.

참고문헌 (99)

  1. Ait Ouakrim D, "Screening participation for people at increased risk of colorectal cancer due to family history : a systematic review and meta-analysis", Fam Cancer, 12, pp.459~472 (2013)
  2. Turati F, "Family history of liver cancer and hepatocellular carcinoma", Hepatology, 55, pp.1416~1425 (2012)
  3. Win AK, "Family history and risk of endometrial cancer : a systematic review and meta-analysis", Obstet Gynecol, 125, pp.89~98 (2015)
  4. Inoue M, "Epidemiology of pancreatic cancer in Japan : a nested case-control study from the Hospitalbased Epidemiologic Research Program at Aichi Cancer Center(HERPACC)", Int J Epidemiol, 32, pp.257~262 (2003)
  5. Falk RT, "Lifestyle risk factors for pancreatic cancer in Louisiana : a case-control study", Am J Epidemiol, 128, pp.324~336 (1988)
  6. Coughlin SS, "Predictors of pancreatic cancer mortality among a large cohort of United States adults", Cancer Causes Control, 11, pp.915~923 (2000)
  7. Hemminki K, "Familial and second primary pancreatic cancers : a nationwide epidemiologic study from Sweden", Int J Cancer, 103, pp.525~530 (2003)
  8. Matsubayashi H, "Risk factors of familial pancreatic cancer in Japan : current smoking and recent onset of diabetes", Pancreas, 40, pp.974~978 (2011)
  9. Klein AP, "Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds", Cancer Res, 64, pp.2634~2638 (2004)
  10. Petersen GM, "Familial pancreatic cancer", Semin Oncol, 43, pp.548~553 (2016)
  11. Giardiello FM, "Very high risk of cancer in familial Peutz-Jeghers syndrome", Gastroenterology, 119, pp.1447~1453 (2000)
  12. Whitcomb DC, "Hereditary pancreatitis and pancreatic carcinoma", Ann N Y Acad Sci, 880, pp.201~209 (1999)
  13. Lynch HT, "Pancreatic cancer and the FAMMM syndrome", Fam Cancer, 7, pp.103~112 (2008)
  14. Vasen HF, "Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16(p16-Leiden)", Int J Cancer, 87, pp.809~811 (2000)
  15. Lynch HT, "Familial pancreatic carcinoma in Jews", Fam Cancer, 3, pp.233~240 (2004)
  16. Murphy KM, "Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer : deleterious BRCA2 mutations in 17%", Cancer Res, 62, pp.3789~3793 (2002)
  17. Breast Cancer Linkage Consortium, "Cancer risks in BRCA2 mutation carriers", J Natl Cancer Inst, 91, pp.1310~1316 (1999)
  18. Kastrinos F, "Risk of pancreatic cancer in families with Lynch syndrome", JAMA, 302, pp.1790~1795 (2009)
  19. Aarnio M, "Cancer risk in mutation carriers of DNA-mismatch-repair genes", Int J Cancer, 81, pp.214~218 (1999)
  20. Giardiello FM, "Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis", Gut, 34, pp.1394~1396 (1993)
  21. Matsubayashi H, "Familial pancreatic cancer : concept, management and issues", World J Gastroenterol, 23, pp.935~948 (2017)
  22. James TA, "Pancreatic cancer screening : identifying premalignant disease", Future Oncol, 1, pp.191~195 (2005)
  23. Brune KA, "Importance of age of onset in pancreatic cancer kindreds", J Natl Cancer Inst, 102, pp.119~126 (2010)
  24. Del Chiaro M, "Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma", Pancreatology, 7, pp.459~469 (2007)
  25. Yeo TP, "Assessment of"gene-environment"interaction in cases of familial and sporadic pancreatic cancer", J Gastrointest Surg, 13, pp.1487~1494 (2009)
  26. Howes N, "Clinical and genetic characteristics of hereditary pancreatitis in Europe", Clin Gastroenterol Hepatol, 2, pp.252~261 (2004)
  27. Schneider R, "German national case collection for familial pancreatic cancer(FaPaCa) : ten years experience", Fam Cancer, 10, pp.323~330 (2011)
  28. Langer P, "Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer", Gut, 58, pp.1410~1418 (2009)
  29. McFaul CD, "Anticipation in familial pancreatic cancer", Gut, 55, pp.252~258 (2006)
  30. Humphris JL, "Clinical and pathologic features of familial pancreatic cancer", Cancer, 120, pp.3669~3675 (2014)
  31. Takaori K, "Pancreatic intraepithelial neoplasia", Pancreas, 28, pp.257~262 (2004)
  32. Brune K, "Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer", Am J Surg Pathol, 30, pp.1067~1076 (2006)
  33. Shi C, "Increased prevalence of precursor lesions in familial pancreatic cancer patients", Clin Cancer Res, 15, pp.7737~7743 (2009)
  34. Singhi AD, "A histomorphologic comparison of familial and sporadic pancreatic cancers", Pancreatology, 15, pp.387~391 (2015)
  35. Abe T, "Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms", Clin Cancer Res, 13, pp.6019~6025 (2007)
  36. Norris AL, "Familial and sporadic pancreatic cancer share the same molecular pathogenesis", Fam Cancer, 14, pp.95~103 (2015)
  37. Brune K, "Genetic and epigenetic alterations of familial pancreatic cancers", Cancer Epidemiol Biomarkers Prev, 17, pp.3536~3542 (2008)
  38. Roberts NJ, "ATM mutations in patients with hereditary pancreatic cancer", Cancer Discov, 2, pp.41~46 (2012)
  39. Axilbund JE, "Absence of germline BRCA1 mutations in familial pancreatic cancer patients", Cancer Biol Ther, 8, pp.131~135 (2009)
  40. Lynch HT, "BRCA1 and pancreatic cancer : pedigree findings and their causal relationships", Cancer Genet Cytogenet, 158, pp.119~125 (2005)
  41. Goggins M, "Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas", Cancer Res, 56, pp.5360~5364 (1996)
  42. Bartsch DK, "Low frequency of CHEK2 mutations in familial pancreatic cancer", Fam Cancer, 5, pp.305~308 (2006)
  43. Jones S, "Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene", Science, 324, pp.217~ (2009)
  44. Slater EP, "PALB2 mutations in European familial pancreatic cancer families", Clin Genet, 78, pp.490~494 (2010)
  45. Takai E, "Germline mutations in Japanese familial pancreatic cancer patients", Oncotarget, 7, pp.74227~74235 (2016)
  46. Kang E, "The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population : recent update of the Korean Hereditary Breast Cancer(KOHBRA)study", Breast Cancer Res Treat, 151, pp.157~168 (2015)
  47. Cho JH, "BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group", Pancreas, 36, pp.337~340 (2008)
  48. Turner N, "Hallmarks of ‘BRCAness’ in sporadic cancers", Nat Rev Cancer, 4, pp.814~819 (2004)
  49. Figer A, "The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel", Br J Cancer, 84, pp.478~481 (2001)
  50. Martin ST, "Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer", Oncogene, 24, pp.3652~3656 (2005)
  51. Skoulidis F, "Germline Brca2 heterozygosity promotes Kras(G12D) : driven carcinogenesis in a murine model of familial pancreatic cancer", Cancer Cell, 18, pp.499~509 (2010)
  52. Matsubayashi H, "Multiple K-ras mutations in hyperplasia and carcinoma in cases of human pancreatic carcinoma", Jpn J Cancer Res, 90, pp.841~848 (1999)
  53. Petersen GM, "Pancreatic cancer genetic epidemiology consortium", Cancer Epidemiol Biomarkers Prev, 15, pp.704~710 (2006)
  54. Del Chiaro M, "Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach:a position paper from the Italian Registry", Dig Liver Dis, 42, pp.597~605 (2010)
  55. Mocci E, "PanGen-Fam : Spanish registry of hereditary pancreatic cancer", Eur J Cancer, 51, pp.1911~1917 (2015)
  56. Wada K, "Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012", J Hepatobiliary Pancreat Sci, 20, pp.557~566 (2013)
  57. Brand RE, "Advances in counselling and surveillance of patients at risk for pancreatic cancer", Gut, 56, pp.1460~1469 (2007)
  58. Canto MI, "International Cancer of the Pancreas Screening(CAPS)Consortium summit on the management of patients with increased risk for familial pancreatic cancer", Gut, 62, pp.339~347 (2013)
  59. Tanaka M, "International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas", Pancreatology, 12, pp.183~197 (2012)
  60. Egawa S, "Japan Pancreatic Cancer Registry; 30th year anniversary : Japan Pancreas Society", Pancreas, 41, pp.985~992 (2012)
  61. Sud A, "Promising outcomes of screening for pancreatic cancer by genetic testing and endoscopic ultrasound", Pancreas, 43, pp.458~461 (2014)
  62. Lynch SM, "Cigarette smoking and pancreatic cancer : a pooled analysis from the pancreatic cancer cohort consortium", Am J Epidemiol, 170, pp.403~413 (2009)
  63. Larsson SC, "Body mass index and pancreatic cancer risk : a meta-analysis of prospective studies", Int J Cancer, 120, pp.1993~1998 (2007)
  64. Stolzenberg-Solomon RZ, "Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort", Am J Epidemiol, 167, pp.586~597 (2008)
  65. Huxley R, "Type-II diabetes and pancreatic cancer : a meta-analysis of 36 studies", Br J Cancer, 92, pp.2076~2083 (2005)
  66. Lowenfels AB, "Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group", N Engl J Med, 328, pp.1433~1437 (1993)
  67. Talamini G, "Incidence of cancer in the course of chronic pancreatitis", Am J Gastroenterol, 94, pp.1253~1260 (1999)
  68. Tanaka S, "Slight dilatation of the main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer : a prospective study", Radiology, 254, pp.965~972 (2010)
  69. Canto MI, "Screening for early pancreatic neoplasia in high-risk individuals : a prospective controlled study", Clin Gastroenterol Hepatol, 4, pp.766~781 (2006)
  70. Yasuda I, "Role of EUS in the early detection of small pancreatic cancer", Dig Endosc, 23(Suppl 1), pp.22~25 (2011)
  71. Topazian M, "Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds", Gastrointest Endosc, 66, pp.62~67 (2007)
  72. Eisen GM, "Guidelines for credentialing and granting privileges for endoscopic ultrasound", Gastrointest Endosc, 54, pp.811~814 (2001)
  73. Canto MI, "Frequent detection of pancreatic lesions in asymptomatic high-risk individuals", Gastroenterology, 142, pp.796~804 (2012)
  74. Brentnall TA, "Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer", Ann Intern Med, 131, pp.247~255 (1999)
  75. Mucci LA, "Familial risk and heritability of cancer among twins in Nordic countries", JAMA, 315, pp.68~76 (2016)
  76. Canto MI, "Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance", Gastroenterology, 155, pp.740~751 (2018)
  77. Kauff ND, "Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2", J Clin Oncol, 25, pp.2921~2927 (2007)
  78. Nimptsch U, "Nationwide in-hospital mortality following pancreatic surgery in Germany is higher than anticipated", Ann Surg, 264, pp.1082~1090 (2016)
  79. Müller MW, "Is there still a role for total pancreatectomy", Ann Surg, 246, pp.966~974 (2007)
  80. Mehrabi A, "Expanding the indications of pancreas transplantation alone", Pancreas, 43, pp.1190~1193 (2014)
  81. Miyazaki M, "Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy : is it worthwhile", Surgery, 155, pp.58~66 (2014)
  82. Heidt DG, "Total pancreatectomy : indications, operative technique, and postoperative sequelae", J Gastrointest Surg, 11, pp.209~216 (2007)
  83. Canto MI, "Screening for pancreatic neoplasia in high-risk individuals : an EUS-based approach", Clin Gastroenterol Hepatol, 2, pp.606~621 (2004)
  84. Poley JW, "The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer", Am J Gastroenterol, 104, pp.2175~2181 (2009)
  85. Verna EC, "Pancreatic cancer screening in a prospective cohort of high-risk patients : a comprehensive strategy of imaging and genetics", Clin Cancer Res, 16, pp.5028~5037 (2010)
  86. Ludwig E, "Feasibility and yield of screening in relatives from familial pancreatic cancer families", Am J Gastroenterol, 106, pp.946~954 (2011)
  87. Vasen HF, "Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation", Gastroenterology, 140, pp.850~856 (2011)
  88. Al-Sukhni W, "Screening for pancreatic cancer in a high-risk cohort : an eight-year experience", J Gastrointest Surg, 16, pp.771~783 (2012)
  89. Del Chiaro M, "Short-term results of a magnetic resonance imaging-based swedish screening program for individuals at risk for pancreatic cancer", JAMA Surg, 150, pp.512~518 (2015)
  90. Vasen H, "Benefit of surveillance for pancreatic cancer in high-risk individuals : outcome of long-term prospective follow-up studies from three European expert centers", J Clin Oncol, 34, pp.2010~2019 (2016)
  91. Kamisawa T, "Pancreatic cancer", Lancet, 388, pp.73~85 (2016)
  92. Alsop K, "BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer : a report from the Australian Ovarian Cancer Study Group", J Clin Oncol, 30, pp.2654~2663 (2012)
  93. Kaufman B, "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1", 2 mutation, 2015, pp.33, 244~250
  94. Golan T, "Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers", Br J Cancer, 111, pp.1132~1138 (2014)
  95. Lohse I, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts", Br J Cancer, 113, pp.425~432 (2015)
  96. Fogelman D, "Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma", Cancer Chemother Pharmacol, 76, pp.489~498 (2015)
  97. Kondo T, "Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer", Oncotarget, 9, pp.19817~19825 (2018)
  98. O’Sullivan CC, "Beyond breast and ovarian cancers : PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors", Front Oncol, 4, pp.42~ (2014)
  99. Ashworth A, "A synthetic lethal therapeutic approach : poly(ADP)ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair", J Clin Oncol, 26, pp.3785~3790 (2008)

관련 논문AI추천

Familial Pancreatic Cancer and the Future of Directed ScreeningAimee L. Lucas, Sara Welinsky거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제6호Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma공선영, 김윤희, 박상재, 박선화, 심효은, 우상명, 유금혜, 이동은, 조은해, 천정원, 최종문, 한성식대한암학회 · Cancer Research and Treatment2023 · 제55권 제4호Detecting Early Pancreatic Cancer: Current Problems and Future ProspectsHirotoshi Ishiwatari, Hiroyuki Matsubayashi, Hiroyuki Ono, Katsuhiko Uesaka, Keiko Sasaki거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제1호The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer SyndromeAgnieszka Soluch, Aniruddh Kashyap, Cezary Cybulski, Jacek Gronwald, Jan Lubinski, Marcin R. Lener, Sandra Pietrzak, Tomasz Huzarski, Wojciech Kluzniak대한암학회 · Cancer Research and Treatment2017 · 제49권 제2호Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer박승우, 박정엽, 방승민, 송시영, 정문재, 정재복, 정주원거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제5호췌장암 조기 진단을 위한 선별 검사장재혁대한내과학회 · 대한내과학회지2021 · 제96권 제2호

이 간행물의 다른 논문 (14건)

Is a Citric Acid Meal Useful for Increasing Accuracy of the 13C-Urea Breath Test in Asian Populations?Sung Eun Kimpp. 479-480Potential for Peritoneal Metastasis after Gastric Perforation Induced by Endoscopic Submucosal Dissection of Early Gastric CancerBong Eun Leepp. 481-482Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from VietnamPham Hong Khanh, Vu Van Khien, Duong Minh Thang, Tran Manh Hai, Nguyen Quang Duat, Dang Thuy Ha, Tran Thanh Binh, Ho Dang Quy Dung, Tran Thi Huyen Trang, Yoshio Yamaokapp. 483-497Effect of Citric Acid on Accuracy of 13C-Urea Breath Test after Helicobacter pylori Eradication Therapy in a Region with a High Prevalence of Atrophic GastritisYong Hwan Kwon, Dong Ho Lee, Young Soo Park, Na Young Kim, Hyuk Yoon, Cheol Min Shinpp. 506-514Long-term Clinical Outcomes and Risk of Peritoneal Seeding after Endoscopic Submucosal Dissection for Early Gastric Cancer: A Focus on Perforation during the ProcedureJoon Sung Kim, Byung-Wook Kim, Cheal Wung Huh, Gi Jun Kim, Myeongsook Seopp. 515-521
원문 보기